Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.
Lei Lei (pronounced "Lay Lay") joined Endpoints as a news reporter in 2022. She graduated from Cornell University, where she studied biochemistry and had a column in the student paper. She splits her time between New York and New Jersey, and outside of work, you might find her concocting new coffee creations or binge-watching sci-fi shows.